EP2970214A1 - Improved process for the manufacture of moxonidine - Google Patents
Improved process for the manufacture of moxonidineInfo
- Publication number
- EP2970214A1 EP2970214A1 EP14709300.9A EP14709300A EP2970214A1 EP 2970214 A1 EP2970214 A1 EP 2970214A1 EP 14709300 A EP14709300 A EP 14709300A EP 2970214 A1 EP2970214 A1 EP 2970214A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- less
- moxonidine
- preparation
- minutes
- dmaia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 27
- WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 229960003938 moxonidine Drugs 0.000 title claims abstract description 26
- 238000004519 manufacturing process Methods 0.000 title description 4
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- 239000012535 impurity Substances 0.000 claims description 25
- 238000006243 chemical reaction Methods 0.000 claims description 22
- XUKUURHRXDUEBC-SXOMAYOGSA-N (3s,5r)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-SXOMAYOGSA-N 0.000 claims description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 11
- 239000011541 reaction mixture Substances 0.000 claims description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 6
- 235000011181 potassium carbonates Nutrition 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 235000017550 sodium carbonate Nutrition 0.000 claims description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- ZMCUDHNSHCRDBT-UHFFFAOYSA-M caesium bicarbonate Chemical compound [Cs+].OC([O-])=O ZMCUDHNSHCRDBT-UHFFFAOYSA-M 0.000 claims description 2
- 229910000025 caesium bicarbonate Inorganic materials 0.000 claims description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 2
- 235000011089 carbon dioxide Nutrition 0.000 claims description 2
- 239000005457 ice water Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims description 2
- 229910052808 lithium carbonate Inorganic materials 0.000 claims description 2
- HQRPHMAXFVUBJX-UHFFFAOYSA-M lithium;hydrogen carbonate Chemical compound [Li+].OC([O-])=O HQRPHMAXFVUBJX-UHFFFAOYSA-M 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- QGQXAMBOYWULFX-LZWSPWQCSA-N 2-morpholin-4-ylethyl (e)-6-(4,6-dihydroxy-7-methyl-3-oxo-1h-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound OC=1C=2C(=O)OCC=2C(C)=C(O)C=1C\C=C(/C)CCC(=O)OCCN1CCOCC1 QGQXAMBOYWULFX-LZWSPWQCSA-N 0.000 claims 3
- 239000002585 base Substances 0.000 description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000035484 reaction time Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 239000002050 international nonproprietary name Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- GFOAVLDLJHAHLM-UHFFFAOYSA-N n-(4,5-dihydro-1h-imidazol-2-yl)-4,6-dimethoxy-2-methylpyrimidin-5-amine Chemical compound COC1=NC(C)=NC(OC)=C1NC1=NCCN1 GFOAVLDLJHAHLM-UHFFFAOYSA-N 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000012087 reference standard solution Substances 0.000 description 1
- 238000012776 robust process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present Invention relates to a novel process for the preparation of Moxonidlne.
- Moxonidlne may be prepared from the key intermediate 4,e-dichloro-2-meth i-5-(1-acetyl-2- !mIdazoIin-2-yl)-amInopyrimIdIne (hereinafter DMAIA) of structural formula (II):
- U.S. patent No. 4,323,570 discloses a method of preparing Moxonldlne (I) by reacting the compound of formula (II) with sodium methoxkie. in CZ294649, a method of preparing Moxonldlne from DMAIA by a reaction using alkali metal carbonates in methanol Is disclosed.
- EP 1 873 151 suggests the use of bases like sodium hydroxide and potassium hydroxide for ft ⁇ reaction with DMAIA,
- Impurity A 4,6 ⁇ lchloro-N-(lmWazolldln-2-yllder»)-2-methylpyrimldlfr5-amfrie
- Impurity C 5-[(imWazoldIn»2-yldene)amsno
- Impurities A Not more than 0.3%
- Impurity B Not more than 0.3%
- impurity C & D Not more than 0.1%
- the reaction cascade from DMAIA to Moxonidine was believed to include a first deacetylation step resulting in the formation of "impurity A'.
- a first substitution step the first of trie two chlorine atoms Is then substituted by a methoxy-f roup deriving from the solvent methanol, leading to Moxinidirte.
- a consecutive substitution step also the other chlorine subetltuent Is replaced by another methoxy group, directly leading to Impurity B. From Figure 1 is immediately clear that Impurity A is somewhat "underreacted” compared to Moxonidine, since only the acyl group has been removed from DMAIA, but both C!-afoms still remain.
- Impurity B Is somewhat "overreacted” compared to Moxonidine, since not only one Cl-substituent has been replaced by methox - subslituent as in Moxonidine, but both.
- the present Invention provides a process for the commercial production of Moxonidine without the need of an additional crystallization step comprising the following steps.
- Suitable weak bases can be selected from, but are not limited to, potassium carbonate, sodium bicarbonate, sodium carbonate, potassium bicarbonate, lithium carbonate, caesium carbonate, lithium bicarbonate, caesium bicarbonate or mixtures thereof Since strong bases as alkali methoxkfes or alkali hydroxides accelerate the conversion from
- Potassium and/or sodium carbonate are the preferred bases since they do not produce water which may lead to increased amounts of the Impurities C and D.
- the most preferred base is potassium carbonate. i
- the molar ratio of the weak base and DMAIA te within the range of 1.85 to 2.05 equivalents of weak base with respect to DMAIA.
- the use of a less excess of base than 1.95 as suggested In EP 1 873 151 results In a reduced capacity to neutralize the hydrochloric add that Is produced upon substitution of the chlorine atom from DMAIA and leads to an Increase of reaction time needed for completion of the reaction and to Increased amounts of the 'overreacted 8 Impurity B.
- the use of an excess > 2.05 of base with respect to DMAIA results In the formation of higher amounts of inorganic salts that unnecessarily complicate the workup.
- Methanol Is preferably used in a 100- to 120-fold molar excess with respect to DMAIA, ⁇ preferably in a 110- to 120-fold molar excess. It Is important to realize that the adjustment of the methanol content In relation to the content of DMAIA and base is not a simple single parameter optimization, because methanol is not only used as a solvent, but also functions as a reagent at the same time, in addition, DMAIA and the carbonate base are only partly soluble In methanol so that the reaction does not occur in solution, but represents a suspension reaction in heterogeneous phases with complicated equilibriums.
- the reaction temperature Is preferably kept near the boiling point of methanol, i.e. In a range between 60*C and 85'C DMAIA can optionally be added to the suspension of a suitable weak base In methanol at the reaction temperature in 2 to 20 portions, preferably In 5 to 15 portions, even more preferably in 8 to 10 portions.
- a suitable weak base In methanol at the reaction temperature in 2 to 20 portions, preferably In 5 to 15 portions, even more preferably in 8 to 10 portions.
- the reaction of DMAIA is exothermic and takes place In suspension, the technical effect of consecutive addition of portions of DMAIA Is to maintain the reaction temperature constant and to avoid the creation of lumps.
- the mixture Is preferably kept at the reaction temperature less than 30 minutes, even more preferably between 5 and 20 minutes and most preferably between 7 and 12 minutes to complete the conversion from DMAIA to Moxonidine, but avoid overreaction.
- the reaction mixture In order to stop the reaction faster and more efficiently, the reaction mixture to then cooled down to below 30 e C within less than 30 minutes, more preferably cooled down to below 2S*C within less than 30 minutes, and even more preferably cooled down to below 25"C within less than 20 minutes.
- the reaction mixture Is additionally transferred Into a second, pre-cooied reactor within 5 minutes or less, preferably within 3 minutes or less, even more preferably within less than 1 minute.
- the coding process is further enforced by means of inserting ice water and/ or Ice cubes, liquid nitrogen, dry ice and the like into the vessel
- the levels of impurities are reduced to far below 0,3% and total impurities are reduced to far below 0.5%, thus meeting the requirements of PhEur without the need of an additional, time and energy consuming crystallization step, as appears from table 1
- the pH-vaiue is adjusted to pH s 7 with acetic add.
- the reaction mixture is optionally filtered by means of activated charcoal.
- the pH of the filtrate Is then adjusted with ammonia water solution to pH ⁇ 8 and the Moxonldine is isolated, washed with water and methanol and dried.
- impurities are determined via the HPLC-Method established therein, the contents in % being determined via comparison of the peak areas of the respective impurity with the peak of the reference standard solution.
Abstract
The present invention describes a novel process for the preparation of Moxonidine (Formula (I)).
Description
TITLE
Improved process for the manufacture of Moxonldln*
FIELD OF THE INVENTION The present Invention relates to a novel process for the preparation of Moxonidlne.
BACKGROUND OF THE INVENTION
4-CWoro-N-(lmid82»iidlrv2-yM^ has the international non-proprietary name (INN) Moxonldine and is used as an antihypertensive drug. It has the structural formula (I):
Moxonidlne may be prepared from the key intermediate 4,e-dichloro-2-meth i-5-(1-acetyl-2- !mIdazoIin-2-yl)-amInopyrimIdIne (hereinafter DMAIA) of structural formula (II):
U.S. patent No. 4,323,570 discloses a method of preparing Moxonldlne (I) by reacting the compound of formula (II) with sodium methoxkie. in CZ294649, a method of preparing Moxonldlne from DMAIA by a reaction using alkali metal carbonates in methanol Is disclosed. EP 1 873 151 suggests the use of bases like sodium hydroxide and potassium hydroxide for ft© reaction with DMAIA,
The major chaHenga in the reaction of DMAIA to Moxonldlne Is the occurrence of several byproducts. Ph. Eur. lists the following major Impurities:
Impurity A: 4,6^lchloro-N-(lmWazolldln-2-yllder»)-2-methylpyrimldlfr5-amfrie
(β-chloromoxonidine):
N-(imldazolldin-2-ylldBne)-4,8-dimethoxy-2-methylpyrimldln-5-aminB
(4-Methoxy-moxonidine):
Impurity C: 5-[(imWazoldIn»2-yldene)amsno|-8^ethoxy-2-melli^pyrlmWln-4-ol
(4-hydroxymoxonidlne):
6-ditoro.5^(!mfdazolidln-2-ylWene)amfnol-2-rnethyIpyrim!dlne- -ol (6-desmethyimoxonidine)
The limits for Impurities are set up by the PrtEur 7.0 as follows. Impurity A: Not more than 0.3% Impurity B: Not more than 0.3% impurity C & D: Not more than 0.1% Total impurities: Not more than 0.5%
it appears from the processes disclosed In the prior art that, in order to meat the requirements of PhEur with respect to impurities A and B, an additional recrysta!l!zat!on step Is mandatory. For example, out of the total 38 working examples in EP 1 873 151, only Moxonidine obtained according to examples 34 and 36, both including a re-crystaf!izatlon step, meets the limits for Impurity A and B.
The reason why ft is so difficult to obtain low levels of impurities A and B at the same time is clear from the following scheme:
Impurity B Miwanidims
The reaction cascade from DMAIA to Moxonidine was believed to include a first deacetylation step resulting in the formation of "impurity A'. In a first substitution step, the first of trie two chlorine atoms Is then substituted by a methoxy-f roup deriving from the solvent methanol, leading to Moxinidirte. in a consecutive substitution step, also the other chlorine subetltuent Is replaced by another methoxy group, directly leading to Impurity B. From Figure 1 is immediately clear that Impurity A is somewhat "underreacted" compared to Moxonidine, since only the acyl group has been removed from DMAIA, but both C!-afoms still remain. On the other hand, It can be said that Impurity B Is somewhat "overreacted" compared to Moxonidine, since not only one Cl-substituent has been replaced by methox - subslituent as in Moxonidine, but both.
As appears from the prior art, It is practically impossible to produce Moxonidine with both low amounts of Impurity A and Impurity B. If the reaction time was short, there was a lot of underreacted Impurity A remaining. On the other hand, a prolonged reaction time unavoidably resulted in a high amount of "overreacted" Impurity B. Provided that the decrease of Impurity A was Inseparably linked to the Increase of formation of Impurity B, an additional crystallization step had to be applied in order to meet the requirements of PhEur as set out above.
With respect to Impurities C and D, the prior art remains silent However, it Is aseumed that at least from EP 1 873 151 employing hydroxide bases like NaOH and KOH a significant formation of hydrox Mmpurities C & D can be expected.
In addition, none of the prior art references discloses a process for the synthesis of Moxonfd!ne on a commercial scale. The prior art discloses batch sizes of several grams only.
Therefore, there Is a need to produce Moxonidine on a commercial scale and In a good quality.
For the reasons set out above, K was very surprising when the inventors of the present application found a robust process for the synthesis of Moxonidine on a kg-seafe in high yield and In a purity that meets the requirements of PhEur without an additional reoyntBlilzafion step fscrt asn of tne Invention
The present Invention provides a process for the commercial production of Moxonidine without the need of an additional crystallization step comprising the following steps.
- Providing a suspension of a weak base in methanol at a temperature between 50"C and 65*C
- Adding DMAIA to the suspension In several portions
- Keeping the mixture at the reaction temperature for less than one additional hour after the addition of DMAIA is completed
- Cooing the reaction mixture down to below 30"C within lees than 30 minutes
Suitable weak bases can be selected from, but are not limited to, potassium carbonate, sodium bicarbonate, sodium carbonate, potassium bicarbonate, lithium carbonate, caesium carbonate, lithium bicarbonate, caesium bicarbonate or mixtures thereof Since strong bases as alkali methoxkfes or alkali hydroxides accelerate the conversion from
DMAIA Into its substitution products very much, the present process cannot be applied to a reaction with such strong bases.
Potassium and/or sodium carbonate are the preferred bases since they do not produce water which may lead to increased amounts of the Impurities C and D. The most preferred base is potassium carbonate.
i
Preferably the molar ratio of the weak base and DMAIA te within the range of 1.85 to 2.05 equivalents of weak base with respect to DMAIA. The use of a less excess of base than 1.95 as suggested In EP 1 873 151 results In a reduced capacity to neutralize the hydrochloric add that Is produced upon substitution of the chlorine atom from DMAIA and leads to an Increase of reaction time needed for completion of the reaction and to Increased amounts of the 'overreacted8 Impurity B. On the other hand, the use of an excess > 2.05 of base with respect to DMAIA results In the formation of higher amounts of inorganic salts that unnecessarily complicate the workup. Methanol Is preferably used in a 100- to 120-fold molar excess with respect to DMAIA, ■ preferably in a 110- to 120-fold molar excess. It Is important to realize that the adjustment of the methanol content In relation to the content of DMAIA and base is not a simple single parameter optimization, because methanol is not only used as a solvent, but also functions as a reagent at the same time, in addition, DMAIA and the carbonate base are only partly soluble In methanol so that the reaction does not occur in solution, but represents a suspension reaction in heterogeneous phases with complicated equilibriums.
In order to speed up the conversion from DMAIA to Moxonidine as much as possible, the reaction temperature Is preferably kept near the boiling point of methanol, i.e. In a range between 60*C and 85'C DMAIA can optionally be added to the suspension of a suitable weak base In methanol at the reaction temperature in 2 to 20 portions, preferably In 5 to 15 portions, even more preferably in 8 to 10 portions. Keeping in mind that the reaction of DMAIA is exothermic and takes place In suspension, the technical effect of consecutive addition of portions of DMAIA Is to maintain the reaction temperature constant and to avoid the creation of lumps. After the addition of DMAIA the mixture Is preferably kept at the reaction temperature less than 30 minutes, even more preferably between 5 and 20 minutes and most preferably between 7 and 12 minutes to complete the conversion from DMAIA to Moxonidine, but avoid overreaction.
In order to stop the reaction faster and more efficiently, the reaction mixture to then cooled down to below 30eC within less than 30 minutes, more preferably cooled down to below 2S*C within less than 30 minutes, and even more preferably cooled down to below 25"C within less than 20 minutes.
Optionally, the reaction mixture Is additionally transferred Into a second, pre-cooied reactor within 5 minutes or less, preferably within 3 minutes or less, even more preferably within less than 1 minute.
Optionally, the coding process is further enforced by means of inserting ice water and/ or Ice cubes, liquid nitrogen, dry ice and the like into the vessel
The precipitation and further workup of Moxonldlne may be performed as described In the prior art.
As a result of the total process, several advantages occur:
- The total reaction time is reduced drastically from several hours and days to only a few minutes
- Most Importantly, the levels of impurities, especially the levels of impurity A and N- (imldazolWin-2-ylfderw)^6<Um^ {Impurity B), are reduced to far below 0,3% and total impurities are reduced to far below 0.5%, thus meeting the requirements of PhEur without the need of an additional, time and energy consuming crystallization step, as appears from table 1
Finally, the process described above Is suitable also for production on commercial scales, i.e. for batches involving 1 kg or more of DMAIA In high yields.
re ara ve exam les, 1 ft 9 - PrWfflrfttJon of M9» mam
102 kg {128 L, 3014.4 moi) of methanol and 7.7 kg (65.6 mo!) of potassium carbonate are charged into a reactor, the mixture is intensively stirred and heated up to 85*C. 8 kg DMAIA (27,8 moi} are added in 8 portions within 20 minutes. The content of the reactor is kept at 65'C for an additional 7 - 12 minutes under stirring. The reaction is stopped by transferring the whole reaction mixture Into a separate pre-coeled reactor within less than 1 minute and further cooling the reaction mixture down to below 25'C within 20 minutes. tttabiK
The pH-vaiue is adjusted to pH s 7 with acetic add. the reaction mixture is optionally filtered by means of activated charcoal. The pH of the filtrate Is then adjusted with ammonia water solution to pH≥ 8 and the Moxonldine is isolated, washed with water and methanol and dried.
Yield : S2,0 % of theory
Tgpje 1; xonldjrte impurities determined according to ΡηξνΤ 7-0:
in PhEur 7.0, impurities are determined via the HPLC-Method established therein, the contents in % being determined via comparison of the peak areas of the respective impurity with the peak of the reference standard solution.
Claims
1. A process for the preparation of Moxonidine. comprising the steps of
- Providing a suspension of a weak base in methanol at a temperature between SOX and 65*C
- Adding DMAIA to the suspension In several portions
- Keeping the mixture at the reaction temperature for less than one additional hour after the addition of DMAIA is completed
- Cooling the reaction mixture down to below 30*G within less than 30 minutes.
2. The process for the preparation of Moxonidine according to claim 1, wherein the weak base is present In a molar ratio of between 1.95 and 2.05 with respect to DMAIA.
3. The process for the preparation of Moxonidlne according to claim 1 or claim 2, wherein the weak base is selected from one of potassium carbonate, sodium bicarbonate, sodium carbonate, potassium bicarbonate, lithium carbonate, caesium carbonate, lithium bicarbonate, caesium bicarbonate or mixtures thereof.
4. The process for the preparation of Moxonidine according to claim 3, wherein the weak base Is selected from one of potassium carbonate, sodium carbonate or mixtures thereof.
5. The process for the preparation of Moxonidine according to any one of the preceding claims, wherein DMAIA Is added In 2 to 20 portions within less than 1 hour, preferably in 5 to 15 portions within less than 30 minutes, most preferably in B to 10 portions within less than 20 minutes.
6. The process for the preparation of Moxonidlne according to any one of the preceding claims, wherein methanol is present in a 80- to 150-fold molar excess with respect to DMAIA, preferably In a 100- to 130-fold molar excess with respect to DMAIA, most preferably in a 110- to 120-fold molar excess with respect to DMAIA.
7. The process for the preparation of Moxonidine according to any one of the preceding claims, wherein the reaction temperature is kept between 60eC and 65X.
8. The proceM for the preparation of Moxonldlne according to any one of the preceding claims, wherein the mixture is kept at the reaction temperature for less than 30 minutes, preferably between 5 and 20 minutes, most preferably between 7 and 12 minutes after the addition of O A1A is completed.
Θ. The process for the preparation of Moxonldlne according to any one of the preceding claims, wherein the reaction mixture is cooled down to below 25"C within less than 30 minutes, and preferably cooled down to below 25'C within less than 20 minutes.
10. The process for the preparation of Moxonidine according to any one of the preceding claims, wherein the cooling process Is enforced by means of Inserting Ice water and/ or fee cubes, liquid nitrogen or dry ice into the vessel.
11. The process for the preparation of Moxonidine according to any one of the preceding claims, wherein the reaction mixture is transferred Into a separate pre-cooted reactor within 5 minutes or less, preferably within 3 minutes or less, more preferably within less than 1 minute.
12. The process for the preparation of Moxonidine according to any one of the preceding claims on a commercial scale, wherein the amount of DMAIA is 5 kg or more.
13. The process for the preparation of Moxonidine according to any one of the preceding claims, wherein the Moxonidine obtained comprises less man 0.05% 4,6-dichloro-N-
(lroWa2oWln-2-y«dene)-2-methylpyrimIdin-5-amlrie (Impurity A) and 0.18% or less of N-(imlda2oIidir^2.ylldeneH,e^methoxy-2-methylpyrlmWin-6-amirie (Impurity B), the total impurities being 0.28% or less, when determined according to PhEur 7.0.
14. Moxonldlne obtained according to one of the preceding claims without further recrystaMzation, wherein the Moxonidine comprises less than 0.3% 4,6-dlchtoro-N- (Emidazoiidin-2'yfidene)-2-methylpyrimidlrt-5-amine (Impurity A) and less than 0.3% of
N-(imidazo!Idin-2iflkSen^^ (Impurity B), when determined according to PhEur 7.0.
15. Moxonidine obtained according to one of the preceding claims without further rt crystallization, wherein the Moxonidine comprises tern than 0.05% 4,ikitehloro-N-
(imldflzoiidin-2-ylidene)-2-methyipyrlmldln-5^ m!ne (Impurity A) and 0.18% or less of
r^miidazo!id?n-2-y!ktene)^6-tf^ (Impurity B) the total Impurities being 0.28% or less, when determined according to PhEur 7.0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14709300.9A EP2970214A1 (en) | 2013-03-14 | 2014-03-11 | Improved process for the manufacture of moxonidine |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13001305 | 2013-03-14 | ||
| PCT/EP2014/054735 WO2014140034A1 (en) | 2013-03-14 | 2014-03-11 | Improved process for the manufacture of moxonidine |
| EP14709300.9A EP2970214A1 (en) | 2013-03-14 | 2014-03-11 | Improved process for the manufacture of moxonidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP2970214A1 true EP2970214A1 (en) | 2016-01-20 |
Family
ID=47900474
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP14709300.9A Withdrawn EP2970214A1 (en) | 2013-03-14 | 2014-03-11 | Improved process for the manufacture of moxonidine |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP2970214A1 (en) |
| CN (1) | CN105121431A (en) |
| IL (1) | IL240819A0 (en) |
| WO (1) | WO2014140034A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4323570A (en) * | 1978-11-15 | 1982-04-06 | Beiersdorf Aktiengesellschaft | Substituted aminopyrimidines |
| CZ294649B6 (en) * | 2004-02-10 | 2005-02-16 | Farmak, A. S. | Process for preparing 4-chloro-N-(4,5-dihydro-1-H-imidazol-2-yl)-6-methoxy-2-methyl-5-pyrimidinamine |
| ATE407931T1 (en) * | 2006-06-26 | 2008-09-15 | Chemagis Ltd | IMPROVED METHOD FOR PRODUCING MOXONIDINE |
-
2014
- 2014-03-11 EP EP14709300.9A patent/EP2970214A1/en not_active Withdrawn
- 2014-03-11 CN CN201480013663.5A patent/CN105121431A/en active Pending
- 2014-03-11 WO PCT/EP2014/054735 patent/WO2014140034A1/en active Application Filing
-
2015
- 2015-08-25 IL IL240819A patent/IL240819A0/en unknown
Non-Patent Citations (2)
| Title |
|---|
| None * |
| See also references of WO2014140034A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| IL240819A0 (en) | 2015-10-29 |
| CN105121431A (en) | 2015-12-02 |
| WO2014140034A1 (en) | 2014-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006136087A1 (en) | Preparation method of pregabalin and its intermediate and the said intermediate | |
| EP2621909B1 (en) | Process for preparing bosentan monohydrate and its intermediates | |
| CN110878084A (en) | Preparation method of nicosulfuron original drug | |
| TW201429924A (en) | Production method of refined amine compound | |
| CN104402909B (en) | A kind of synthetic method of cefoxitin acid | |
| DK2170829T3 (en) | Process for the preparation of a toluidinforbindelse | |
| CN103965058B (en) | A kind of production technology of memantine | |
| EP2970214A1 (en) | Improved process for the manufacture of moxonidine | |
| CN109661385B (en) | Method for synthesizing 9, 9-bis (hydroxymethyl) fluorene | |
| JP4880332B2 (en) | Method for producing crystalline L-carnosine zinc complex | |
| CN109761914B (en) | Method for preparing 5-trifluoromethyl uracil | |
| CN106866638A (en) | A kind of avanaphil citric acid eutectic and preparation method thereof | |
| CN111303045A (en) | Production process of 2-ethoxy-4, 6-difluoropyrimidine | |
| HU230214B1 (en) | Process for the preparation of quinoline derivatives | |
| CN101709050A (en) | New method for synthesizing 2, 5-dichloropyridine | |
| CN101243064B (en) | (E)-N-monoalkyl-3-oxo-3-(2-thienyl)propenamine and process for producing the same, and process for producing (E,Z)-n-monoalkyl-3-oxo-3-(2-thienyl)propenamine | |
| CN101781212B (en) | Method for synthesizing 2-hydroxymethyl acrylate compound | |
| JP2927880B2 (en) | Method for producing 4,4'-dihydroxy-3,3 ', 5,5'-tetramethyldiphenylmethane | |
| CN114044783B (en) | Preparation method of idosiban and intermediate thereof | |
| JP2013227273A (en) | Purification method for 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazole-2-yl)-benzimidazole-1-yl]-methyl]-biphenyl-2-carboxylic acid | |
| CN110590733B (en) | Synthesis method of 1,4-dioxane-2,5-diol | |
| JP4548894B2 (en) | Method for producing solid water-insoluble organic peroxide | |
| JP5843106B2 (en) | Process for producing 4-substituted piperidine-2-carbonitriles and process for producing 4-substituted piperidine-2-carboxylic acid mineral salts | |
| JP6425980B2 (en) | Process for producing corresponding ketone compounds from ketoxime alkali metal salts or ketoxime alkaline earth metal salts | |
| JP2002534495A (en) | Process for producing azoimino ether and azocarboxylic acid ester and novel mixed azocarboxylic acid ester |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20150924 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| 17Q | First examination report despatched |
Effective date: 20161031 |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| INTG | Intention to grant announced |
Effective date: 20180424 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20180905 |